Bermekimab

DB14947Investigational

Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).

Mechanism: Pharmacologically active on Interleukin-1 alpha
Curator reviewed
Also known as: RA-18C3
Code names: CA-18C3

Resolves to

Compound

UNIIN6SVN735GYCAS1401965-15-8

Clinical / RWD

ATCL01FX11

Targets

P01583IL1A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

421Drug interactionsStructured to mechanism, not free text

15Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 12 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bermekimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account